Pathway Analysis for Genome-Wide Association Study of Basal Cell Carcinoma of the Skin by Zhang, Mingfeng et al.
Pathway Analysis for Genome-Wide Association Study of
Basal Cell Carcinoma of the Skin
Mingfeng Zhang
1,2*, Liming Liang
3,4, Mousheng Xu
4, Abrar A. Qureshi
1,5, Jiali Han
1,4,5
1Department of Dermatology, Clinical Research Program, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America,
2Department of Epidemiology and Biostatistics, Cancer Center, Nanjing Medical University, Nanjing, China, 3Department of Biostatistics, Harvard School of Public Health,
Boston, Massachusetts, United States of America, 4Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America,
5Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
Abstract
Background: Recently, a pathway-based approach has been developed to evaluate the cumulative contribution of the
functionally related genes for genome-wide association studies (GWASs), which may help utilize GWAS data to a greater
extent.
Methods: In this study, we applied this approach for the GWAS of basal cell carcinoma (BCC) of the skin. We first conducted
the BCC GWAS among 1,797 BCC cases and 5,197 controls in Caucasians with 740,760 genotyped SNPs. 115,688 SNPs were
grouped into gene transcripts within 20 kb in distance and then into 174 Kyoto Encyclopedia of Genes and Genomes
pathways, 205 BioCarta pathways, as well as two positive control gene sets (pigmentation gene set and BCC risk gene set).
The association of each pathway with BCC risk was evaluated using the weighted Kolmogorov-Smirnov test. One thousand
permutations were conducted to assess the significance.
Results: Both of the positive control gene sets reached pathway p-values,0.05. Four other pathways were also significantly
associated with BCC risk: the heparan sulfate biosynthesis pathway (p = 0.007, false discovery rate, FDR = 0.35), the
mCalpain pathway (p = 0.002, FDR = 0.12), the Rho cell motility signaling pathway (p = 0.011, FDR = 0.30), and the nitric
oxide pathway (p = 0.022, FDR = 0.42).
Conclusion: We identified four pathways associated with BCC risk, which may offer new insights into the etiology of BCC
upon further validation, and this approach may help identify potential biological pathways that might be missed by the
standard GWAS approach.
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Introduction
Recently, genome-wide association studies (GWASs) have
o f t e nb e e nc o n d u c t e dt oinvestigate the genetic susceptibility to
complex diseases, including skin cancer [1]. Cancer of the skin
(including both melanoma and non-melanoma skin cancers) is
the most common form of cancer, accounting for more than
50% of all cancers. Basal cell carcinoma (BCC) accounts for
approximately 80 percent of all non-melanoma skin cancers,
and its incidence is increasing [2]. Although GWASs have
identified several new loci associated with BCC [3,4], the most
significant SNPs that fulfilled a stringent statistical ‘‘genome-
wide’’ significance criterion often account for only a small
proportion of genetic susceptibility. More attention should be
paid to the rest of the genetic information, which may offer a
deeper understanding of the genetics of complex diseases [5].
Combining the modest association signals in the GWAS data
with information on biological pathways and networks, the
emerging pathway-based approaches are designed to utilize the
GWAS data to a greater extent and are likely to yield new
insights into disease etiology [6].
It has been suggested that multiple susceptibility genes for a
single disease tend to have some related functions or aggregate in
certain pathways [7]. For example, some genes associated with
BCC risk are related to pigmentation [1]. The pathway-based
approach, which evaluates the cumulative contribution of the
functionally related genes, may help uncover the associations of
genes with small effect sizes that cluster within common biological
pathways [6]. Using an approach based on the gene-set
enrichment analysis algorithm [8], pathway analyses have been
applied to the GWASs of several complex diseases, and some novel
candidate disease-susceptibility pathways have been revealed
[9,10,11,12].
Here we report on the results of a pathway analysis on GWAS
of BCC to identify the biological pathways associated with BCC
risk, which may provide new insights into the etiology of BCC.
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BCC GWAS
Ethics Statement. This study was approved by the Human
Research Committee at the Brigham and Women’s Hospital
(Boston, MA) with written informed consent from all participants.
Description of Study Populations. The BCC GWAS
comprised 1,797 BCC cases and 5,197 controls, which were
from four pre-existing GWAS sets [13,14]. The description of
BCC GWAS dataset was presented in a manuscript currently in
press [15]. Briefly, the four component GWAS sets reflect the
type 2 diabetes case-control study nested within the Nurses’
Health Study (T2D_NHS, BCC cases=665, BCC
controls=2,162), the type 2 diabetes case-control study nested
within the Health Professionals Follow-up Study (T2D_HPFS,
BCC cases=597, BCC controls=1,555), the coronary heart
disease case-control study nested within the NHS (CHD_NHS,
BCC cases=253, BCC controls=765), and the coronary heart
disease case-control study nested within the HPFS
(CHD_HPFS, BCC cases=282, BCC controls=715). All the
cases were self-reported BCC patients, and we excluded those
who had diagnosis of other common cancers before diagnosis of
BCC based on common cancers reported by the National
Cancer Institute and American Cancer Society. For BCC
controls, we also excluded those individuals who had diagnosis
of BCC or other common cancers. Those common cancers
included melanoma, SCC, breast cancer, endometrial cancer,
ovarian cancer, colorectal cancer, bladder cancer, lung cancer,
pancreatic cancer, kidney (renal cell) carcinoma, leukemia, Non-
Hodgkin Lymphoma, thyroid cancer, and oral cancer.
Overlapping individuals among the four GWAS sets were
removed. All the individuals in our study are of European
ancestry and live in the United States. The study protocol was
approved by the Institutional Review Boards of Brigham and
Women’s Hospital and the Harvard School of Public Health.
Detailed descriptions of the study populations for each study are
presented in the Methods S1.
Genotyping and Quality Control. We used the genotype
data from four pre-existing GWAS sets (T2D_NHS, T2D_HPFS,
CHD_NHS, and CHD_HPFS) [13]. The genotyping was
previously conducted using the Affymetrix 6.0 array and the
information on genotyping and quality control was previously
described [13]. For each study, the detailed information was
summarized in the Methods S1.
Association analysis. Associations between each SNP and
BCC risk were determined using a multivariable logistic regression
model; Age and the first three principal components of genetic
variation (Methods S1) were adjusted in the model within each of
the four sets. The case-control status of T2D and CHD was also
adjusted in the sensitivity analysis. For each SNP, within-cohort
association results were combined in an inverse variance–weighted
meta-analysis using METAL software [16].
Pathway data construction
We collected pathway data from the Kyoto Encyclopedia of
Genes and Genomes (KEGG) and BioCarta databases; 174
KEGG pathways and 205 BioCarta pathways that contain at least
10 but at most 200 genes represented by qualified SNPs were
tested. The cutoff of 10–200 genes was selected as a good balance
for gene sets to reduce the multiple-testing issue and to avoid
testing overly narrow or broad functional categories. We also
designed two positive control gene sets, the pigmentation gene set
and BCC risk gene set, to test this approach. We selected the genes
based on information gathered by the previous GWAS studies on
the pigmentation traits and BCC risk. The pigmentation gene set
included SLC45A2, IRF4, EXOC2, TYPR1, TPCN2, TYR, KITLG,
SLC24A4, OCA2, MC1R, ASIP, HERC2; and the BCC risk gene set
included PADI6, RHOU, SLC45A2, TERT, CLPTM1L, KLF14,
CDKN2A, CDKN2B, TYR, KRT5, MC1R, ASIP, PTCH1.
Statistical Method of the Pathway Analysis
We applied the method of Wang et al. [11] to conduct the
pathway-based GWAS analysis. Specifically, we first calculated the
statistic value for the association of each SNP with BCC risk.
Then, we associated the SNPs located within 20 kb upstream or
downstream of gene transcript with each gene, and assigned the
highest statistical value among all the SNPs located in this region
as representative of this gene. All the genes were assigned to
pathways as previously defined. Then the association of each
pathway with BCC (denoted by Enrichment Score, ES) was
evaluated using the weighted Kolmogorov-Smirnov-like running
sum statistic, which reflects the overrepresentation of genes within
this pathway at the top of the entire ranked list of genes in the
genome. We used a permutation procedure (1,000 permutations,
permuting the case-control status and re-calculating the pathway-
based ES) to assess the significance of the statistical value. A
normalized enrichment score was calculated for each pathway to
allow direct comparison of pathways of different sizes. The false
discovery rate (FDR) was calculated to keep the proportion of
expected false positive findings below a certain threshold [17]. We
set the significance level for the pathway analysis as p value,0.05
and FDR,0.5. The detailed algorithm of pathway analysis was
described by Wang et al [11].
Results
Basic characteristics of the 1,797 BCC cases and 5,197 controls
in our study are presented in Table S1. As shown in the table, the
BCC cases were more likely to have red or blonde hair and
lifetime severe sunburns that blistered, and they tended to have
poorer ability to tan than the controls (Table S1).
Of the 740,760 genotyped SNPs, 366,550 SNPs located within
20 kb upstream or downstream of gene transcripts were assigned
to the genes. Among them, 115,688 SNPs were ultimately assigned
to 4,891 genes within the pre-defined pathways (107,521 SNPs to
4,538 genes in the KEGG pathways and 34,301 SNPs to 1,298
genes in the BioCarta pathways). A total of 174 KEGG pathways
and 205 BioCarta pathways that contained between 10 and 200
eligible genes were used for the pathway analysis.
Both of the positive control gene sets reached a nominal p-
value,0.05 (p = 0.001 for the pigmentation gene set and p =
0.03 for the BCC risk gene set). As shown in Table S2, 10 out of 12
genes in the pigmentation gene set had representative SNPs that
reached p value,0.05 for the association with BCC (range 0.02 to
3.4E-7, and the two that did not reach significance had p values of
0.05 and 0.09), and seven out of 13 genes in the BCC risk gene set
had SNPs with p value,0.05 (range 0.03 to 3.4E-7, and the
remaining six had p values from 0.11 to 0.16).
Besides the two positive control gene sets, 10 out of the 174
KEGG pathways and eight out of the 205 BioCarta pathways
reached a significance level of p,0.05, and four also reached a
FDR of less than 0.5. Those were the heparan sulfate biosynthesis
pathway (p = 0.007, FDR = 0.35), the mCalpain pathway (p =
0.002, FDR = 0.12), the Rho cell motility signaling pathway (p =
0.011, FDR = 0.30), and the nitric oxide pathway (p = 0.022,
FDR = 0.42, Table 1). Complete association results for all the
pathways in the KEGG database are listed in Table S3 (a), and
those in the BioCarta database are listed and Table S3 (b)).
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pathway had SNPs with p-value for marginal effect on BCC risk
(PBCC),0.05; the same was true for 14 out of 24 genes in the
mCalpain pathway, 16 out of 32 genes in the Rho cell motility
signaling pathway, and 16 out of 30 genes in the nitric oxide
pathway. The representative SNP of each gene in the four
pathways that had PBCC,0.01 are listed in Table 1, and the
representative SNPs of all the genes in these pathways are listed in
Table S4.
According to the pathway definition in the BioCarta
d a t a b a s e ,t h e r ea r es o m eo v e r l a p sb e t w e e nt h em C a l p a i n
pathway (24 genes) and the other two pathways: 3 genes
(MYLK, MYL2 and TLN1) in the Rho cell motility signaling
pathway (32 genes); and 6 genes (PRKACG, PRKACB, PRKAR2B,
PRKAR1A, PRKAR1B, PRKAR2A) in the nitric oxide pathway (30
genes). After excluding the 3 genes shared between the
mCalpain pathway and the Rho cell motility signaling pathway,
the association obviously attenuated for both pathways (p =
0.04 and FDR = 0.61 for the mCalpain pathway, and p = 0.05
and FDR = 0.84 for the Rho cell motility signaling pathway).
The association remained similar after excluding the 6 genes
shared between the mCalpain pathway (p = 0.003 and FDR =
0.12) and the nitric oxide pathway (p = 0.04 and FDR = 0.76).
No other overlap was found among the remaining pathways. In
addition, based on the concern that the case-control status of
T2D and CHD may introduce potential bias to the associations
between the SNPs and BCC risk, a sensitivity analysis was
conducted by adjusting for the case-control status. As a result,
no substantial change was detected for the associations before
and after the adjustment.
Table 1. Pathways with significant enrichment in the BCC GWAS.
Database Pathway Gene Count
1 FDR
2
Pathway
Enrichment p-value
Genes with
PBCC,0.01
3 SNP
4 SNP PBCC
KEGG Heparan sulfate
biosynthesis pathway
19 0.35 0.007 HS3ST3A1 rs8074072 1.93E-03
HS6ST2 rs7881124 2.37E-03
HS6ST3 rs8002510 3.43E-03
HS6ST1 rs11890277 5.43E-03
HS3ST1 rs1024034 6.45E-03
EXTL3 rs12544882 9.74E-03
EXT2 rs7950395 9.75E-03
BioCarta mCalpain pathway 24 0.18 0.002 ITGA1 rs1833556 2.69E-04
MYLK rs820455 8.99E-04
EGF rs6824594 9.55E-04
CAPNS2 rs4784549 6.13E-03
PXN rs11611541 7.07E-03
PRKACG rs1590944 8.31E-03
ITGB1 rs7079624 8.66E-03
BioCarta Rho cell motility
signalling pathway
32 0.30 0.011 MYLK rs820455 8.99E-04
ROCK1 rs1481280 9.06E-04
BAIAP2 rs9903763 1.44E-03
OPHN1 rs5965550 3.70E-03
PIP5K1B rs963707 4.37E-03
ACTR3 rs2279839 4.84E-03
ARHGEF1 rs11665965 5.40E-03
BioCarta Nitric oxide pathway 30 0.42 0.022 VEGFA rs13211073 4.54E-04
RYR2 rs2805434 9.35E-04
PRKG1 rs10762543 1.92E-03
BDKRB2 rs874284 4.73E-03
NOS3 rs3763486 7.79E-03
CHRM1 rs4592425 8.24E-03
PRKACG rs1590944 8.31E-03
TNNI1 rs6697016 8.70E-03
1The number of the genes with SNPs tested in BCC GWAS;
2Based on 1000 permutations, with 174 tested pathways for KEGG darabase and 205 tested pathways for Biocarta darabase;
3PBCC is p-value of SNP for BCC association. Only the genes whose representative SNPs reached PBCC,0.01 are listed here and the information of all enriched genes in the
four pathways are listed in Table S3;
4Representative SNP for each gene with the smallest PBCC.
doi:10.1371/journal.pone.0022760.t001
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Genome-wide association studies primarily focus on marginal
effects for individual markers. Given that some of the susceptibility
genes for a given disease share related functions, a pathway-based
approach that evaluates the cumulative contribution of the
functionally related genes can utilize GWAS data to a greater
extent. This method has recently shown its potential strength in
application to GWASs in several complex diseases [9,10,11,12].
Here we report the results of a pathway analysis to investigate the
GWAS associations for BCC. Gene-sets that contained pigmenta-
tion genes or BCC risk genes identified from previous GWASs were
significantly associated with BCC in our pathway analysis, which
suggests that the pathway-based approach can effectively incorpo-
rate the modest effects of genes with related functions. In addition,
we identified four other pathways significantly associated with BCC
risk as defined by the KEGG and BioCarta databases: the heparan
sulfate biosynthesis pathway, the mCalpain pathway, the Rho cell
motility signaling pathway, and the nitric oxide pathway.
The mCalpain pathway ranked first among the 205 BioCarta
pathways tested in this study (p = 0.002 and FDR = 0.18).
Calpain is a class of Ca
2+-dependent cysteine proteases with two
major ubiquitously expressed isoforms: m-calpain (or calpain I) and
m-calpain (or calpain II). One of the most carefully studied
functions of the calpains is the regulation of integrin-mediated cell
migration [18]. mCalpain is believed to be membrane bound and
functions at the trailing edge of the migrating cell to cleave the
integrins in response to growth factor receptor signals [18,19],
which may play a role in the invasion of tumor cells into
surrounding stroma during the development of BCC. In addition
to cell migration, a number of protein substrates of calpains have
been identified as playing very important roles in cell proliferation,
apoptosis, and cell cycle control [20,21,22,23,24]. The assessed m-
calpain expression level appeared to be inversely correlated to
apoptotic activity in various cell types [20,25], and the over-
expression of m-calpain has been detected in human cancer [26].
To date, calpain inhibitors have been used widely to trigger
apoptosis in various cancer cell lines [27]. However, as for BCC,
only one study has reported that the expression of u-calpain in
BCCs was markedly elevated compared to normal human skin,
and no difference was found for m-calpain [28]. In our study,
although we detected only a weak association between the m-
calpain polymorphisms and BCC risk (representative p = 0.05), a
stronger association was identified for the m-calpain pathway,
which suggests that m-calpain has its effects through interaction
with other genes in the pathway.
The other two pathways associated with BCC risk in the
BioCarta database were the Rho cell motility signaling pathway
and the nitric oxide pathway. After excluding the genes shared
with the mCalpain pathway, the association for the Rho cell
motility signaling pathway became non-significant, suggesting that
the association was driven by the genes shared with the mCalpain
pathway. There is evidence from previous study that calpain
mediates integrin-induced signaling at a point upstream of Rho
family members [29]. It is certainly plausible that BCC
tumorigenesis requires the mCalpain pathway for local invasion
into the epidermis and through the basement membrane zone into
the dermis. Another plausible explanation is an integrin-mediated
immune response that requires adhesion of circulating anti-tumor
T cells to the dermal endothelial cells followed by migration of T
cells into tissues – an aberration of a T cell response to BCC may
allow the tumor to grow unabated in skin.
The association of the nitric oxide pathway remained significant
after excluding the genes shared with the mCalpain pathway,
which suggests an independent effect. Nitric oxide (NO) is a
signaling molecule that plays a critical role in vasodilatation,
neurotransmission and immunity, and has been shown to be
cytostatic or cytotoxic for cancer cells [30]. NO is also produced in
the skin and its associated microvasculature, and has complex
implications in skin homeostasis and diseases [31]. The NO
pathway in the BioCarta database focuses mainly on the sub-
network of NOS3. NOS3, also named as endothelial cell
constitutive NOS or eNOS, plays an important role in the
regulation of vascular endothelial function [32], and the expression
of NOS3 was reported to be down-regulated in basal cell
carcinomas when compared with normal skin [33]. A significant
association was also detected between NOS3 polymorphisms and
BCC risk in our study (representative p = 0.01). A characteristic
clinical feature of BCCs is a translucent papule or nodule with
prominent telangiectasia, presumably an angiogenic response
propagated by the growing skin cancer. A NOS-predominant
BCC may potentially be able to attract a risk blood supply for
continued growth and NOS (via NOS inhibitors) may be
considered a therapeutic target.
As for the KEGG pathways, the heparan sulfate biosynthesis
pathway was significantly associated with BCC risk (p = 0.007
and FDR = 0.35). Heparan sulfate (HS) is a glycosaminoglycan
covalently attached to serine residues in a proteoglycan core
protein. Heparan sulfate proteoglycans (HSPGs) have been known
to play vital roles in every step of tumor progression: allowing
cancer cells to proliferate, escape from immune response, invade
neighboring tissues, and metastasize to distant sites [34]. Several
cancers including melanoma have shown aberrant modulation of
several key HS biosynthetic enzymes [35,36,37,38]. However, no
study has been reported on BCC, and our finding suggests the
potential importance of this pathway in the etiology of BCC,
relevant in the case of nodular or morpheaform BCCs where
dermal invasion is commonly seen.
There are some limitations to our approach. First, current
knowledge on human gene functions is incomplete, and the pre-
defined pathways cannot comprehensively represent the function-
ally related genes in the human genome. We used the KEGG and
BioCarta pathways in this study, which represent relatively well-
defined known biological pathways. To minimize multiple-testing
concerns, we did not include some other pathway databases with
more broad functional categories such as the Gene Ontology (GO)
[39,40]. Secondly, the assignment of SNPs to genes in physical
proximity may not always be accurate. A gene may be regulated in
trans by genetic variants that are physically distant from the
structural gene [41]. Third, given the modest sample size, the
FDRs of the identified pathways are not particularly low. Further
replication using additional samples and functional investigation
would be required to illustrate the true effect behind these
pathways.
In conclusion, we applied a pathway-based approach to further
explore the GWAS data of BCC and identified several pathways
associated with BCC risk, which was missed in the traditional
GWAS. These findings may suggest new insights into the etiology
of BCC upon further replication. Functional studies are also
warranted to characterize the biological functions of these
pathways in BCC development.
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